metastatic/advanced - colorectal cancer (mCRC) | |
mCRC - 1st line (L1) | |
atezolizumab plus FOLFOXIRI plus bevacizumab | AtezoTRIBE |
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-